Trial Profile
Safety and Efficacy of SPARC1203 in Allergic Rhinitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs SUN 0597 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Sun Pharma Advanced Research Company
- 23 Jun 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2012-001613-16).
- 14 Jun 2012 New trial record
- 13 Jun 2012 Planned end date changed from 1 Oct 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.